SCHEDULE 13G/A: Janus Henderson Group Discloses 5.6% Passive Stake in Entrada Therapeutics
Ownership Disclosure
Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 5.6% in Entrada Therapeutics, Inc.'s common stock as of March 31, 2025.
Summary
- Janus Henderson Group plc, a global asset manager, and its affiliates, including Janus Henderson Biotech Innovation Master Fund Ltd, have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Entrada Therapeutics, Inc. common stock.
- As of March 31, 2025, Janus Henderson Group plc beneficially owns an aggregate of 2,121,654 shares of Entrada Therapeutics, Inc. common stock, representing 5.6% of the class.
- Janus Henderson Biotech Innovation Master Fund Ltd, an investment company, beneficially owns 1,884,826 shares, representing 5.0% of the class.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of Entrada Therapeutics, Inc., indicating a passive investment strategy.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine disclosure of passive beneficial ownership and does not contain performance or strategic updates from the issuer.
Future Outlook
NA
Industry Context
This filing reflects a significant institutional investment in a biotechnology company, which is common for large asset managers with specialized sector funds. It indicates continued institutional interest in Entrada Therapeutics, Inc. from a major investment firm.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, which can be viewed as a vote of confidence from a major investor, although it is a passive stake and does not imply active management involvement.
- Company Management: Awareness of a significant passive institutional investor in the company's common stock.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date of Power of Attorney execution by Janus Henderson Group plc. |
| 2025-03-31 | Date of event which requires the filing of this statement. |
| 2025-05-14 | Date of filing and signature by Kristin Mariani, Head of North America Compliance, CCO for both reporting persons. |
Keywords
Entrada Therapeutics, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment Management, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.